You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Preclinical Development of a Novel and Powerful Immunotherapeutic
SBC: IMMURX LLC Topic: NIAIDDESCRIPTION (provided by applicant): ImmuRx is developing a novel and potent immunotherapeutic product to stimulate the immune system. This will significantly increase the efficacy of existing and new therapeutic vaccines for the treatment of cancers suchas melanoma, lymphoma and lung cancer and for chronic infectious diseases such as Hepatitis C. The barrier to the induction of protective, thera ...
SBIR Phase II 2011 Department of Health and Human ServicesNational Institutes of Health -
CF Corrector Ligands Discovered on CF Human Airway Cells
SBC: DISCOVERYBIOMED, INC. Topic: NIDDKDESCRIPTION (provided by applicant): DiscoveryBioMed, Inc. (DBM) achieved Phase 1 SBIR milestones and seeks to continue a mature program that has progressed to the hit-to-lead drug validation, prioritization and progression stage. DBM s major over-archinggoal for this program is to identify novel clinical candidate CFTR Corrector Ligands (CFCLs) for the treatment of CF through the completion of a ...
SBIR Phase II 2011 Department of Health and Human ServicesNational Institutes of Health -
Regulatory Advancement of HXe as a Diagnostic MRI Contrast Agent
SBC: XEMED LLC Topic: NHLBIDESCRIPTION (provided by applicant): New therapies are in development for COPD (endobronchial valves/stents/glue) and asthma (endobronchial thermal ablation). Hyperpolarized xenon-129 (HXe) MRI, a noninvasive method to assess regional lung structure and function, may prove critical in the guidance of these regional treatments. In our prior work we developed an innovative approach to xenon polariza ...
SBIR Phase II 2011 Department of Health and Human ServicesNational Institutes of Health -
Nanotechnology Enabled Temporomandibular Joint(TMJ)Prosthesis
SBC: VISTA ENGINEERING, INC. Topic: NIDCRDESCRIPTION (provided by applicant): Temporomandibular Disorders (TMD) represent a collection of medical and dental conditions affecting the temporomandibular joint (TMJ) and/or the muscles of mastication, as well as contiguous tissue structures. For somepatients with severe TMJ degeneration, a prosthetic replacement may be required. However, long-term success and functioning of current implant d ...
STTR Phase II 2011 Department of Health and Human ServicesNational Institutes of Health -
Development of an extremely efficient nebulizer for intranasal vaccination
SBC: CREARE LLC Topic: N/AExtremely Efficient Nebulizer for Intranasal Vaccination. Specifically the nasal delivery device could reduce health care associated infections by providing a needle-free method of delivery of vaccines and therapeutics which are currently delivered by injection with all the attendant risks of transmission of blood borne disease through needle-stick injury and unsafe needle practices. One of the m ...
SBIR Phase II 2011 Department of Health and Human ServicesCenters for Disease Control and Prevention -
Microfluidic High-throughput Platform for Determining Kinetic Constants of Enzyme Variants
SBC: CFD RESEARCH CORPORATION Topic: CBD10107Current high-throughput platforms rely on labeled substrates that produce detectable spectroscopic signals upon reaction for monitoring enzyme catalytic activity. Add to that the high price tag for these instruments, ranging from several hundred thousand to millions of dollars, and there is a clear need for alternate solutions for a label-free, low-cost, high-throughput enzyme screening platform. ...
SBIR Phase II 2011 Department of DefenseOffice for Chemical and Biological Defense -
A Novel Microfludic Device for Drug Toxicity Studies
SBC: CFD RESEARCH CORPORATION Topic: CBD10103Current drug discovery and development efforts are severely limited by expensive animal trials and oversimplified in vitro models. Results obtained from in vitro models are not predictive of in vivo toxicity owing to significant difference from the in vivo physiological conditions. In this context, we propose to develop and demonstrate a novel microfluidic device that reproduces the physiological ...
SBIR Phase II 2011 Department of DefenseOffice for Chemical and Biological Defense